Debbie Robbrecht

Dr. Debbie Robbrecht is a researcher in the Department of Medical Oncology at Erasmus MC, a leading academic medical center in the Netherlands. Her work is highly focused on translational and clinical oncology, particularly in urothelial and prostate cancers, with a strong emphasis on advanced diagnostics and novel therapeutics.

Her research interests span a range of critical areas in modern oncology, including molecular biomarkers, targeted radionuclide therapy, pharmacokinetics/pharmacodynamics, and whole genome sequencing for cancer of unknown primary. She actively investigates how emerging imaging technologies such as PSMA PET/CT influence clinical decision-making and patient management.

The recent articles highlight a consistent trend toward integrating precision medicine into oncology practice. Her work frequently involves multidisciplinary collaboration and evaluates real-world applications of cutting-edge therapies, including Lu-PSMA and immunocytokines. The publications reflect deep engagement with clinical trial design, treatment personalization, and biomarker validation across solid tumors.

Dr. Robbrecht has no listed scientific awards in the provided text. However, her extensive publication record in high-impact journals suggests significant contributions to the field.

She is involved in collaborative research projects, often working with teams across Erasmus MC and external institutions. These collaborations span nuclear medicine, medical oncology, urology, and molecular diagnostics, indicating her role in integrated cancer care research. While no direct information about student supervision or grant funding is available, her position as a co-investigator on multiple clinical studies implies involvement in research mentoring and project leadership.

She is associated with advanced oncology research initiatives at Erasmus MC, particularly those involving molecular imaging and targeted therapies. Her work contributes to shaping clinical pathways in prostate and urothelial cancers through evidence generation from real-world data and prospective trials.